NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03274492,"A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma",https://clinicaltrials.gov/study/NCT03274492,POLARIX,ACTIVE_NOT_RECRUITING,"This Phase III, randomized, double-blind, placebo-controlled study will compare the efficacy, safety, and pharmacokinetics of polatuzumab vedotin plus R-CHP versus R-CHOP in participants with previously untreated diffuse large B-cell lymphoma (DLBCL).",NO,Diffuse Large B-Cell Lymphoma,DRUG: Polatuzumab Vedotin|DRUG: Rituximab|DRUG: Cyclophosphamide|DRUG: Doxorubicin|DRUG: Vincristine|DRUG: Vincristine Placebo|DRUG: Prednisone|DRUG: Polatuzumab vedotin Placebo,"Progression-Free Survival (PFS) as Assessed by the Investigator, Using the Lugano Response Criteria for Malignant Lymphoma, From randomization to the first occurrence of disease progression or relapse, or death from any cause, whichever occurs earlier (up to 38 months)","Percentage of Participants With Complete Response (CR) as Assessed by Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) by Blinded Independent Central Review (BICR), End of treatment visit (6-8 weeks after last dose on Day 1 of Cycle 8 [Cycle length=21 days] [up to Week 32])|Event-Free Survival-Efficacy (EFSeff) as Assessed by the Investigator, Using the Lugano Response Criteria for Malignant Lymphoma, From randomization to first occurrence of disease progression/relapse;or death from any cause;or other primary efficacy reason that leads to initiation of any non-protocol specified antilymphoma treatment(NALT);or residual disease(up to approx 65 months)|Percentage of Participants Who are Progression Free as Assessed by the Investigator, Using the Lugano Response Criteria for Malignant Lymphoma, 24 months after enrollment (up to approximately 65 months)|Overall Survival, From randomization until death from any cause (up to approximately 65 months)|Percentage of Participants With CR as Assessed by FDG-PET by Investigator, End of treatment visit (6-8 weeks after last dose on Day 1 of Cycle 8 [Cycle length=21 days] [up to Week 32])|Disease-Free Survival (DFS) as Assessed by the Investigator, Using the Lugano Response Criteria for Malignant Lymphoma, From the date of first occurrence of a documented CR to the date of relapse or death from any cause (up to approximately 65 months)|Duration of Response as Assessed by the Investigator, Using the Lugano Response Criteria for Malignant Lymphoma, From the date of first occurrence of a documented CR or partial response (PR) to the date of progression, relapse, or death from any cause (up to approximately 65 months)|Event-Free Survival-All Causes (EFSall) as Assessed by the Investigator, Using the Lugano Response Criteria for Malignant Lymphoma, From randomization to disease progression or relapse, or death from any cause, or initiation of any NALT (up to approximately 65 months)|Time to Deterioration in European Organisation for Research and Treatment of Cancer Quality of Life-Core 30 Questionnaire (EORTC QLQ-C30) Physical Functioning and Fatigue, Day 1 of Cycles 1, 2, 3 and 5 (Cycle length=21 days); treatment completion visit (TCV)/early treatment termination visit (ETTV) (up to approximately 32 weeks); post-treatment follow-up (FU) visit (up to approximately 65 months)|Time to Deterioration in Functional Assessment of Cancer Therapy-Lymphoma Lymphoma Subscale (FACT-Lym LymS), Day 1 of Cycles 1, 2, 3 and 5 (Cycle length=21 days); TCV/ETTV (up to approximately 32 weeks); post-treatment FU visit (up to approximately 65 months)|Percentage of Participants Achieving Meaningful Improvement in EORTC QLQ-C30 Physical Functioning and Fatigue, Day 1 of Cycles 1, 2, 3 and 5 (Cycle length=21 days); TCV/ETTV (up to approximately 32 weeks); post-treatment FU visit (up to approximately 65 months)|Percentage of Participants Achieving Meaningful Improvement in FACT-Lym LymS, Day 1 of Cycles 1, 2, 3 and 5 (Cycle length=21 days); TCV/ETTV (up to approximately 32 weeks); post-treatment FU visit (up to approximately 65 months)|EORTC QLQ-C30 Treatment-Related Symptoms Score, Day 1 of Cycles 1, 2, 3 and 5 (Cycle length=21 days); TCV/ETTV (up to approximately 32 weeks); post-treatment FU visit (up to approximately 65 months)|Functional Assessment of Cancer Treatment/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-NTX) Peripheral Neuropathy Score, Day 1 of Cycles 1-8 (Cycle length=21 days); TCV/ETTV (up to approximately 32 weeks); post-treatment FU visit (up to approximately 65 months)|Percentage of Participants With adverse Events (AEs), From randomization to the end of study (up to approximately 65 months)|Serum Concentration of Total Polatuzumab Vedotin, Pre-infusion (0 hour [hr]), 0.5 hr post-infusion (infusion duration=90 minutes [min]) on Day 1 of Cycle 1 and 4 (Cycle length=21 days); TCV/ETTV (up to approximately 32 weeks); post-treatment FU visit (up to approximately 65 months)|Plasma Concentration of Polatuzumab Vedotin Conjugate (Antibody-Conjugated Mono-Methyl Auristatin E [acMMAE]), 0.5 hr post-infusion (infusion duration=90 min) on Day 1 of Cycle 1 and 4 (Cycle length=21 days); TCV/ETTV (up to approximately 32 weeks); post-treatment FU visit (up to approximately 65 months)|Plasma Concentration of Polatuzumab Vedotin Unconjugated MMAE, 0.5 hr post-infusion (infusion duration=90 min) on Day 1 of Cycle 1 and 4 (Cycle length=21 days); TCV/ETTV (up to approximately 32 weeks); post-treatment FU visit (up to approximately 65 months)|Percentage of Participants With Anti-Drug Antibody (ADA) to Polatuzumab Vedotin, Pre-infusion (0 hr) on Day 1 of Cycle 1 and 4 (Cycle length=21 days); TCV/ETTV (up to approximately 32 weeks); post-treatment FU visit (up to approximately 65 months)",,Hoffmann-La Roche,,ALL,"ADULT, OLDER_ADULT",PHASE3,1000,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",GO39942|2017-002023-21,2017-11-16,2026-07-05,2026-07-05,2017-09-07,,2025-03-27,"University of Alabama at Birmingham, Birmingham, Alabama, 35294, United States|Southern Cancer Center, Daphne, Alabama, 36526, United States|City of Hope, Duarte, California, 91010, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, 90095, United States|Rocky Mountain Cancer Centers, LLP, Aurora, Colorado, 80012, United States|Georgetown University Medical Center, Washington, District of Columbia, 20007, United States|Florida Cancer Specialists - Fort Myers (New Hampshire Ct), Fort Myers, Florida, 33901-8101, United States|Florida Cancer Specialists & Research Institute, Saint Petersburg, Florida, 33705, United States|Florida Cancer Specialists, West Palm Beach, Florida, 33401, United States|Emory University, Atlanta, Georgia, 30322, United States|Illinois Cancer Specialists, Arlington Heights, Illinois, 60005, United States|University of Louisville Hospital, Louisville, Kentucky, 40202, United States|Ochsner Medical Center, New Orleans, Louisiana, 70121, United States|University of Maryland, Baltimore, Maryland, 21201, United States|Johns Hopkins University, Baltimore, Maryland, 21287, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02115, United States|University of Michigan Health System, Ann Arbor, Michigan, 48109, United States|Karmanos Cancer Center, Detroit, Michigan, 48201, United States|Washington University, Saint Louis, Missouri, 63110, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, 07645, United States|Roswell Park Cancer Institute, Buffalo, New York, 14263, United States|Memorial Sloan Kettering Cancer Center - Commack, Commack, New York, 11725, United States|Memorial Sloan Kettering Cancer Center at Westchester, Harrison, New York, 10604, United States|New York University Cancer Cen, New York, New York, 10016, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|University of Rochester Medical Center, Rochester, New York, 14642, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, 27514, United States|Levine Cancer Institute - Clincal Trials Administration, Charlotte, North Carolina, 28204, United States|Oncology/Hematology Care Clinical Trials LLC, Cincinnati, Ohio, 45236, United States|University Hospitals Case Medical Center, Cleveland, Ohio, 44106, United States|Ohio State University, Columbus, Ohio, 43210, United States|Oncology Associates of Oregon, P.C, Eugene, Oregon, 97401, United States|Northwest Cancer Specialists - Portland (SW Barnes Rd), Portland, Oregon, 97225, United States|Oregon HSU, Portland, Oregon, 97239, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, United States|University of Pittsburgh Medical Center Cancer Center, Pittsburgh, Pennsylvania, 15232, United States|Medical University of South Carolina Hospital, Charleston, South Carolina, 29425, United States|Prisma Health ? Upstate, Greenville, South Carolina, 29615, United States|Greco-Hainesworth Centers for Research, Chattanooga, Tennessee, 37403, United States|Tennessee Oncology - Nashville, Nashville, Tennessee, 37203, United States|Texas Oncology-Austin Midtown, Austin, Texas, 78705, United States|Texas Oncology San Antonio Medical Center, San Antonio, Texas, 78229, United States|Texas Oncology-Tyler, Tyler, Texas, 75702, United States|University of Utah, Salt Lake City, Utah, 84112, United States|Oncology Associates of Southwest Virginia, Inc., Blacksburg, Virginia, 24060, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, 22031, United States|Seattle Cancer Care Alliance, Seattle, Washington, 98101, United States|West Virginia Uni Med. Center - Robert Byrd Health Science, Morgantown, West Virginia, 26506, United States|Concord Repatriation General Hospital, Concord, New South Wales, 2139, Australia|St George Hospital, Kigarah, New South Wales, 2217, Australia|Prince of Wales Hospital, Randwick, New South Wales, 2031, Australia|Calvary Mater Newcastle, Waratah, New South Wales, 2298, Australia|Westmead Hospital, Westmead, New South Wales, 2145, Australia|Princess Alexandra Hospital Woolloongabba, Woolloongabba, Queensland, 4102, Australia|Ashford Cancer Center Research, Kurralta Park, South Australia, 5037, Australia|The University of Adelaide - The Queen Elizabeth Hospital (TQEH), Woodville South, South Australia, 5011, Australia|Monash Medical Centre, Clayton, Victoria, 3168, Australia|Austin Hospital, Heidelberg, Victoria, 3084, Australia|Paracelsus Medizinischen Privatuniversitaet-Salzburger Landeskliniken (SALK), Salzburg, 5020, Austria|Medizinische Universität Wien, Wien, 1090, Austria|Wiener Gesundheitsverbund ? Klinik Ottakring, Wien, 1160, Austria|UZ Gent, Gent, 9000, Belgium|CH Jolimont - Lobbes (Jolimont), Haine-Saint-Paul, 7100, Belgium|CHU UCL Mont-Godinne, Mont-godinne, 5530, Belgium|Hospital Erasto Gaertner, Curitiba, Paraná, 81520-060, Brazil|Hospital das Clinicas - UFRGS, Porto Alegre, Rio Grande Do Sul, Brazil|Centro de Hematologia e Hemoterapia - HEMOCENTRO UNICAMP, Campinas, São Paulo, 13083-878, Brazil|Hospital das Clinicas - FMUSP, Sao Paulo, São Paulo, 05403-000, Brazil|University of Alberta Hospital, Edmonton, Alberta, T6G 1Z2, Canada|BC Cancer ? Vancouver, Vancouver, British Columbia, V5Z 4E6, Canada|CancerCare Manitoba (CCMB), Winnipeg, Manitoba, MB R3E 0V9, Canada|The Ottawa Hospital, Ottawa, Ontario, K1H 8L6, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, M4N 3M5, Canada|CIUSSS de l Est de l Ile de Montreal - Hopital Maisonneuve Rosemont, Montreal, Quebec, H1T 2M4, Canada|CHU de Quebec-Universite Laval, Quebec, G1J 1Z4, Canada|Beijing Cancer Hospital, Beijing, 100142, China|The First Hospital of Jilin University, Changchun City, 130021, China|Fujian Provincial Cancer Hospital, Fuzhou City, 350014, China|Sun Yet-sen University Cancer Center, Guangzhou, 510060, China|The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, 310003, China|Jiangsu Cancer Hospital, Nanjing, 210009, China|Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai City, 200025, China|Shanghai East Hospital, Tongji University, Shanghai City, 200032, China|Fudan University Shanghai Cancer Center, Shanghai, 200032, China|Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin City, 300020, China|Tianjin Medical University Cancer Institute & Hospital, Tianjing, 300060, China|Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan City, 430022, China|Henan Cancer Hospital, Zhengzhou, 450008, China|Fakultni Nemocnice Hradec Kralove (FNHK), Hradec Kralove, 500 05, Czechia|Fakultni nemocnice Olomouc, Olomouc, 775 20, Czechia|Fakultni nemocnice Ostrava, Ostrava - Poruba, 708 52, Czechia|Fakultni Nemocnice Kralovske Vinohrady (FNKV), Prague, 100 34, Czechia|Univerzita Karlova v Praze 1. Lekarska Fakulta, Prague, 128 08, Czechia|CHU Amiens - Hopital Sud, Amiens, 80054, France|CHU Angers, Angers, 49933, France|Centre Hospitalier de La Cote Basque, Bayonne, 64109, France|Hopital Jean Minjoz, Besancon, 25030, France|Institut Bergonie, Bordeaux, 33076, France|Institut d'Hématologie de Basse Normandie, Caen, 14000, France|CH Metropole de Savoie, CHAMBERY Cedex, 73011, France|Hopital Henri Mondor, Creteil, 94010, France|CHU de Dijon - Hopital le Bocage, Dijon, 21000, France|L'Union Mutualiste de la Gestion des Eaux Claires - Institut Daniel Hollard, Grenoble, 38000, France|CHD Vendée, La Roche Sur Yon, 85025, France|Hôpital Albert Michallon, La Tronche, 38700, France|Clinique Victor Hugo - Centre Jean Bernard, Le Mans Cedex 02, 72015, France|Hôpital Saint Vincent de Paul, Lille, 59000, France|Hopital Claude Huriez, Lille, 59037, France|Hopital Uni Ire Dupuytren, Limoges, 87042, France|Centre Leon Berard, Lyon, 69008, France|CHU Montpellier - Saint ELOI, Montpellier, 34295, France|CHU de Nantes - Hotel Dieu, Nantes, 44093, France|Centre Antoine Lacassagne, Nice, 06189, France|CHU de Nîmes - Hôpital Carémeau, Nimes, 30029, France|Hôpital Saint-Louis, Paris, 75475, France|Gh Necker Enfants Malades, Paris, 75743, France|Hopital Saint Jean, Perpignan, 66046, France|Hopital Haut-Leveque - Centre Francois Magendie, Pessac, 33604, France|CHU Lyon Sud - Service Hématologie, Pierre Benite, 69310, France|CHU de Poitiers, Poitiers, 86021, France|Centre Hospitalier de Quimper Cornouaille (CHIC), Quimper Cedex, 29107, France|Hopital Pontchaillou, Rennes, 35033, France|Centre Henri Becquerel, Rouen, 76038, France|Centre Hospitalier de Saint Brieuc - Hôpital Yves Le Foll, St Brieuc, 22027, France|Pôle de Cancérologie ? CHU de Saint?Etienne', St Priest en Jarez, 42270, France|Chru de Strasbourg, Strasbourg, 67091, France|Institut Universitaire du Cancer - Oncopole Toulouse (IUCT-O), Toulouse, 31059, France|CHU Bretonneau, Tours, 37044, France|CHU de Brabois, Vandoeuvre Les Nancy, 54511, France|CH Bretagne Atlantique, Vannes Cedex, 56017, France|Institut Gustave Roussy, Villejuif, 94805, France|Vivantes Klinikum Am Urban, Berlin, 10967, Germany|Städtisches Klinikum Dessau, Dessau-Roßlau, 06847, Germany|Universitätsklinikum Essen, Essen, 45147, Germany|Universitaetsklinikum Halle (Saale), Halle, 06120, Germany|Universitaetsklinikum Heidelberg, Heidelberg, 69120, Germany|InVO - Institut für Versorgungsforschung in der Onkologie GbR, Koblenz, 56068, Germany|Universitatsklinikum Munster, Münster, 48149, Germany|Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Abruzzo, 24060, Italy|Universita degli Studi Di Brescia - Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Abruzzo, Italy|Universita degli Studi di Roma ''La Sapienza"" - Clinica Ematologica, Rome, Abruzzo, Italy|AUSL di Reggio Emilia, IRCCS, P.O. Arcispedale Santa Maria Nuova, Reggio Emilia, Emilia-Romagna, Italy|IRCCS AOU San Martino - IST, Genova, Liguria, 16132, Italy|Istituto Nazionale dei Tumori, Monza, Lombardia, 20052, Italy|Azienda Ospedaliero Universitaria Maggiore della Carita di Novara, Novara, Piemonte, 28100, Italy|Azienda Ospedaliera Universitaria Citta della Salute e della Scienza di Torino, Torino, Piemonte, 00126, Italy|Aichi Cancer Center, Aichi, 464-8681, Japan|Chiba Cancer Center, Chiba, 260-8717, Japan|National Cancer Center Hospital East, Chiba, 277-8577, Japan|Chiba University Hospital, Chuo-ku, 260-8670, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka, 811-1395, Japan|Kyushu University Hospital, Fukuoka, 812-8582, Japan|Hiroshima University Hospital, Hiroshima, 734-8551, Japan|Hokkaido University Hospital, Hokkaido, 060-8648, Japan|Kobe City Medical Center General Hospital, Hyogo, 650-0047, Japan|Tokai University Hospital, Isehara-shi, 259-1193, Japan|Kumamoto University Hospital, Kumamoto, 860-8556, Japan|University Hospital Kyoto Prefectural University of Medicine, Kyoto, 602-8566, Japan|Tohoku University Hospital, Miyagi, 980-8574, Japan|Osaka Metropolitan University Hospital, Osaka, 545-8586, Japan|Osaka University Hospital, Osaka, 565-0871, Japan|Kindai University Hospital, Osaka, 589-8511, Japan|Jichi Medical University Hospital, Tochigi, 329-0498, Japan|National Cancer Center Hospital, Tokyo, 104-0045, Japan|The Cancer Institute Hospital of JFCR, Tokyo, 135-8550, Japan|Pusan National University Hospital, Busan, 49241, Korea, Republic of|National Cancer Center, Gyeonggi-do, 410-769, Korea, Republic of|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Severance Hospital, Seoul, 03722, Korea, Republic of|Asan Medical Center, Seoul, 05505, Korea, Republic of|Samsung Medical Center, Seoul, 06351, Korea, Republic of|Pusan National University Yangsan Hospital, Yangsan, Korea, Republic of|Auckland City Hospital, Cancer and Blood Research, Auckland, 1023, New Zealand|Canterbury Health Laboratories, Christchurch, 8140, New Zealand|Waikato Hospital, Hamilton, 3240, New Zealand|Wojewódzki Szpital Specjalistyczny im. M. Kopernika, ?ód?, 93-510, Poland|Samodzielny Publiczny Zak?ad Opieki Zdrowotnej Zespó? Szpitali Miejskich w Chorzowie, Chorzów, 41-500, Poland|PRATIA MCM Kraków, Kraków, 30-727, Poland|SPZOZ Ministerstwa Spraw Wewn?trznych i Administracji w Poznaniu, Pozna?, 60-631, Poland|Wojskowy Instytut Medyczny - Panstwowy Instytut Badawczy, Warszawa, 04-141, Poland|Leningrad Regional Clinical Hospital, St Petersburg, Sankt Petersburg, 194291, Russian Federation|Complejo Hospitalario de Navarra, Pamplona, Navarra, 31008, Spain|Hospital Universitari Vall d'Hebron, Barcelona, 08035, Spain|Hospital Clinic Barcelona, Barcelona, 08036, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, 08041, Spain|Institut Catala d Oncologia Hospitalet, Barcelona, 08908, Spain|Hospital San Pedro de Alcantara, Caceres, 10003, Spain|Hospital Universitari Dr. Josep Trueta, Girona, 17007, Spain|Hospital Universitario La Paz, Madrid, 280146, Spain|Fundación Jimenez Díaz, Madrid, 28040, Spain|Hospital Quiron Madrid, Madrid, 28233, Spain|Hospital Universitario Virgen de la Victoria, Malaga, 29010, Spain|Hospital Universitario Virgen del Rocio, Sevilla, 41013, Spain|Universitätsspital Basel Gynäkologie - Onkologie, Basel, 4031, Switzerland|Kaohsiung Medical University Hospital, Cancer Center, Kaohsiung, 807, Taiwan|China Medical University Hospital, Taichung, 40447, Taiwan|Chi-Mei Hospital, Liouying, Tainan, 736, Taiwan|National Taiwan University Hospital, Taipei, 10002, Taiwan|Taipei Veterans General Hospital, Taipei, 11211, Taiwan|Ankara University Faculty of Medicine Cebeci Hospital, Ankara, 06700, Turkey|Ege Üniversitesi Tip Fakültesi, Lzmir, 35100, Turkey|Dokuz Eylul Universitesi Tip Fakultesi, Lzmir, 35340, Turkey|Communal Institution 'Cherkassy Regional Oncology Dispensary' of the Cherkassy Regional Council, Cherkassy, Chernihiv Governorate, Ukraine|MNE Lviv Territorial Medical Association Clinical Hospital for Palliative Care, Lviv, Chernihiv Governorate, 79007, Ukraine|Khmelnytskyi Regional Hospital, Khmelnytskyi, Kharkiv Governorate, 29000, Ukraine|Feofaniya Center of Haematology and Chemotherapy of Haemoblastosis, Kyiv, Volhynian Governorate, 03143, Ukraine|Cambridge University Hospitals NHS Foundation Trust - Addenbrookes Hospital, Cambridge, CB2 0QQ, United Kingdom|East Kent Hospitals University NHS Foundation Trust, Canterbury, CT1 3NG, United Kingdom|University Hospitals of Leicester NHS Trust - Leicester Royal Infirmary, Leicester, LE1 5WW, United Kingdom|Barts Health NHS Trust, London, EC1A 7BE, United Kingdom|The Christie NHS Foundation Trust, Manchester, M20 4BX, United Kingdom|The Newcastle upon Tyne Hospitals NHS Foundation Trust. Freeman Hospital, Newcastle upon Tyne, NE7 7DN, United Kingdom|Nottingham City Hospital, Nottingham, NG5 1PB, United Kingdom|Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE, United Kingdom",
